homocysteine has been researched along with levodopa in 97 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.03) | 18.7374 |
1990's | 2 (2.06) | 18.2507 |
2000's | 51 (52.58) | 29.6817 |
2010's | 32 (32.99) | 24.3611 |
2020's | 11 (11.34) | 2.80 |
Authors | Studies |
---|---|
Fuller, RW; Hemrick-Leucke, SK; Perry, KW | 1 |
Joseph, JA; Miller, JW; Nadeau, MR; Selhub, J; Shukitt-Hale, B; Villalobos-Molina, R | 1 |
Fowler, B; Kuhn, W; Müller, T; Werne, B | 1 |
Kowa, H; Nakashima, K; Nakaso, K; Takeshima, T; Yasui, K | 2 |
Brattström, L | 1 |
Hummel, T; Kuhn, W; Müller, T; Woitalla, D | 1 |
Müller, T | 3 |
Blandini, F; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Samuele, A | 1 |
Fowler, B; Hauptmann, B; Kuhn, W; Müller, T; Woitalla, D | 1 |
Fowler, B; Kuhn, W; Müller, T; Woitalla, D | 1 |
Diaz-Arrastia, R; Frol, AB; Rogers, JD; Sanchez-Saffon, A | 1 |
Kowa, H; Kusumi, M; Nakashima, K; Nakaso, K; Sasaki, K; Takeshima, T; Ueda, K; Yasui, K; Yoshimoto, Y | 1 |
Feldman, RG; Miller, JW; Nadeau, MR; Selhub, J; Thomas, CA; Wolf, PA | 1 |
Lökk, J | 1 |
Di Rocco, A; Werner, P | 1 |
Fuchs, D; Leblhuber, F; Schroecksnadel, K | 1 |
Diaz-Arrastia, R; O'Suilleabhain, P | 1 |
Kuhn, W; Müller, T; Renger, K | 1 |
Brosnan, JT; Brosnan, ME; Jacobs, RL; Stead, LM | 2 |
Lang, AE; Postuma, RB | 1 |
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Livrea, P; Zoccolella, S | 1 |
Helkamaa, T; Larjonmaa, H; Nissinen, E; Nissinen, H; Rauhala, P; Reenilä, I; Väänänen, A | 1 |
Hefter, H; Hueber, R; Jost, WH; Leenders, KL; Müller, T; Odin, P; Schwarz, J | 1 |
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Mastronardi, R; Zoccolella, S | 1 |
Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S | 1 |
Bronstein, J; Guarnieri, M; Hubble, J; Kang, GA; Ostrem, JL; Rabinowicz, AL; Subramanian, I | 1 |
Benetin, J; Blazícek, P; Gmitterová, K; Kukumberg, P; Valkovic, P; Valkovicová, L | 1 |
Bostantjopoulou, S; Frangia, T; Hatzizisi, O; Katsarou, Z; Kazis, A; Kiosseoglou, G; Kyriazis, G; Papazisis, K | 1 |
Armenise, E; de Mari, M; Defazio, G; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S | 1 |
Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K | 1 |
Bottiglieri, T; Diaz-Arrastia, R; Greenberg, SM; Growdon, JH; Gurol, ME; Hyman, BT; Irizarry, MC; Locascio, JJ; Raju, S; Tennis, M | 1 |
Kuhn, W; Müller, T | 3 |
Dzoljić, E; Kostić, V; Krajinović, M; Mirković, D; Nesić, Z; Novaković, I; Prostran, M; Stojanović, R; Todorović, Z | 1 |
Armenise, E; de Mari, M; Defazio, G; Dell'Aquila, C; Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, P; Lamberti, SV; Livrea, P; Zoccolella, S | 1 |
Barcikowska, M; Chodakowska-Zebrowska, M; Czyzewski, K; Lokk, J; Peplonska, B; Religa, D; Stepien, K; Styczynska, M; Winblad, B | 1 |
Camicioli, R; Espay, AJ; Lafontaine, AL; Lang, AE; Martin, WR; Postuma, RB; Ranawaya, R; Suchowersky, O; Zadikoff, C | 1 |
Defazio, G; Lamberti, P; Livrea, P; Martino, D; Zoccolella, S | 1 |
Henninger, N; Krause, M; Okun, JG; Schwab, S; Wang, Q | 1 |
Aydemir, T; Cetin, S; Hanoglu, L; Koldas, M; Meral, H; Ozer, F; Ozturk, O; Seval, H; Yilsen, M | 1 |
Blandini, F; Martignoni, E; Nappi, G; Pacchetti, C; Tassorelli, C; Zangaglia, R | 1 |
Armstrong, VW; Bachmann, CG; Guth, N; Happe, S; Helmschmied, K; Paulus, W | 1 |
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Di Iorio, W; Gorgone, G; Ientile, R; Menichetti, C; Parisi, G; Parnetti, L; Pisani, F; Rossi, A | 1 |
Brown, MS; Furtado, S; Suchowersky, O; Toth, C; Zochodne, D | 1 |
Bouchard, TP; Camicioli, RM; Somerville, MJ | 1 |
Hlustik, P; Kanovsky, P; Langova, K; Nevrly, M; Vranova, H | 2 |
Barchak, AG; Busanello, EN; Camargo, D; Carrion, MJ; da Costa, JC; Dalbem, A; de Mello Rieder, CR; de Sousa Miguel, SR; dos Santos, EF; Miglioranza, A; Rosa, C; Saute, J; Vargas, CR; Wajner, M; Zanatta, A | 1 |
Abruzzese, G; Antonini, A; Bonuccelli, U; Canesi, M; Cristina, S; Defazio, G; dell'Aquila, C; Lamberti, P; Livrea, P; Logroscino, G; Marchese, R; Pacchetti, C; Zagaglia, R; Zoccolella, S | 1 |
Muhlack, S; Müller, T | 2 |
Chiang, TR; Ho, CS; Hu, CJ; Hung, YL; Sheu, JJ; Tseng, IJ; Yeh, CY; Yu, JM; Yuan, RY | 1 |
Barone, P; De Bonis, ML; Galletti, P; Ingrosso, D; Longo, K; Pellecchia, MT; Russo, A; Salvatore, A; Tedeschi, G; Tessitore, A; Zappia, V | 1 |
Litvinenko, IV; Mogil'naya, VI; Odinak, MM; Perstnev, SV | 1 |
Chun, S; Chung, SJ; Kim, BJ; Kim, GS; Kim, HK; Kim, MJ; Kim, SR; Koh, JM; Lee, MC; Lee, SH; Ryu, JS | 1 |
Belcastro, V; Calabresi, P; Castrioto, A; Gorgone, G; Ientile, R; Menichetti, C; Pierguidi, L; Pisani, F; Rossi, A; Tambasco, N | 1 |
Abe, T; Isobe, C; Terayama, Y | 1 |
Antonini, A; Bareggi, SR; Bondiolotti, G; Natuzzi, F | 1 |
Iliceto, G; Lamberti, P; Lamberti, SV; Logroscino, G; Santamato, A; Zoccolella, S | 1 |
Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T | 1 |
Muhlack, S; Müller, T; Woitalla, D | 1 |
Garlipp, CR; Gobbi, LT; Gobbi, S; Nascimento, CM; Santos, RF; Stella, F | 1 |
Belcastro, V; Caccamo, D; Calabresi, P; Currò, M; Ferlazzo, N; Gorgone, G; Ientile, R; Parisi, G; Parnetti, L; Pisani, F; Rossi, A; Tambasco, N | 1 |
Ahn, YH; Lee, PH; Paik, MJ; Park, HJ; Shin, JY; Sohn, YH | 1 |
Hu, LF; Hu, XW; Li, D; Liu, CF; Qin, SM | 1 |
Li, Q; Liu, W; Sun, YN; Wang, Y; Yang, JF; Zhang, BS; Zhang, W; Zhao, P | 1 |
Abbruzzese, G; Bandettini di Poggio, M; Barone, P; Bonuccelli, U; Borelli, P; Ceravolo, R; Contu, P; Cossu, G; Frosini, D; Iodice, R; Lopiano, L; Manca, D; Manganelli, F; Marchese, R; Melis, M; Mereu, A; Merola, A; Nicoletti, V; Paribello, A; Picillo, M; Santoro, L; Zibetti, M | 1 |
Antonini, A; Calandrella, D; Cantello, R; Coletti Moja, M; Comi, C; Dal Fante, M; Lacerenza, M; Mancini, F; Manfredi, L; Oggioni, GD; Pacchetti, C; Riboldazzi, G; Tunesi, S | 1 |
Ludwichowska, A; Szabat, K; Szadejko, K; Sławek, J | 1 |
Camicioli, R; Emery, D; Gee, M; Sabino, J; Sapkota, S | 1 |
Hong, JM; Lee, JS; Lee, PH; Yong, SW; Yoon, JH | 1 |
Bhattacharjee, N; Borah, A; Choudhury, A; Choudhury, S; Mazumder, MK; Paul, R | 1 |
Cao, LD; Guo, G; Wu, QY; Xu, S | 1 |
Comoglu, SS; Guven, H; Kocer, B | 1 |
Feng, H; Peng, S; Xiao, J; Xie, Y; Zhang, J | 1 |
Herrman, L; Kinkel, M; Muhlack, S; Müller, T | 1 |
Kang, K; Ko, PW; Lee, HW; Park, D; Park, JS | 1 |
Andréasson, M; Brodin, L; Laffita-Mesa, JM; Svenningsson, P | 1 |
Čierny, D; Grofik, M; Kurča, E; Michalik, J; Nosáľ, V; Sivák, Š; Tatarková, Z; Turčanová Koprušáková, M | 1 |
Dong, Q; Fang, L; Li, J; Liao, J; Lu, T; Lu, Z; Peng, F; Qin, F; Qiu, W; Sun, X; Xu, X | 1 |
Jadavji, NM; Murray, LK | 1 |
Chen, L; Gu, C; Li, D; Li, J; Zhu, M; Zhu, X | 1 |
Baik, JS; Lee, JJ | 1 |
Anamnart, C; Kitjarak, R | 1 |
de Almeida, AG; Finsterer, J; Rodrigues, AM; Scorza, CA; Scorza, FA | 1 |
Bai, Y; Gu, R; Jiang, X; Jiang, Y; Pan, Y; Shen, B; Wang, Y; Yan, J; Zhang, L; Zhong, M; Zhu, J; Zhu, S | 1 |
Chen, J; Cheng, XY; Gu, HY; Jin, H; Li, K; Liu, CF; Liu, MH; Mao, CJ; Xiong, YT; Zhang, JR | 1 |
Müller, T; Schlegel, E; Thiede, HM; Zingler, S | 1 |
Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P | 1 |
Ahlskog, JE | 1 |
Bhidayasiri, R; Garcia-Ruiz, P; Müller, T; Odin, P; Phokaewvarangkul, O; Riederer, P | 1 |
Gao, F; Gao, L; Miao, J; Yang, Y | 1 |
17 review(s) available for homocysteine and levodopa
Article | Year |
---|---|
Non-dopaminergic drug treatment of Parkinson's disease.
Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists | 2001 |
[Treatment with levodopa can affect latent vitamin B 12 and folic acid deficiency. Patients with Parkinson disease runt the risk of elevated homocysteine levels].
Topics: Animals; Antiparkinson Agents; Biomarkers; Blood-Brain Barrier; Folic Acid Deficiency; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12 Deficiency | 2003 |
Methylation demand: a key determinant of homocysteine metabolism.
Topics: Animals; Creatine; Guanidinoacetate N-Methyltransferase; Homocysteine; Humans; Levodopa; Methylation; Methyltransferases; Models, Biological; Models, Chemical; Parkinson Disease; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; Rats | 2004 |
Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?
Topics: Antiparkinson Agents; Arteriosclerosis; Catechol O-Methyltransferase; Dementia; Disease Progression; Disease Susceptibility; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Levodopa; Models, Biological; Multicenter Studies as Topic; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra | 2004 |
Methylation demand and homocysteine metabolism.
Topics: Animals; Homocysteine; Humans; Levodopa; Methionine Adenosyltransferase; Methylation; Methyltransferases; Niacin; Phosphatidylethanolamine N-Methyltransferase; S-Adenosylmethionine | 2004 |
Is levodopa toxic?
Topics: Animals; Dose-Response Relationship, Drug; Homocysteine; Humans; Levodopa; Nerve Degeneration; Neurotoxins; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2004 |
Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses.
Topics: Adolescent; Adult; Animals; Case-Control Studies; Catechol O-Methyltransferase; Cystathionine beta-Synthase; Dopamine Agents; Dystonia; Homocysteine; Humans; Huntington Disease; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 2006 |
Homocysteine and Parkinson's disease: a dangerous liaison?
Topics: Brain; Brain Diseases, Metabolic; Causality; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Nerve Degeneration; Parkinson Disease | 2007 |
Role of homocysteine in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease, Secondary | 2008 |
Hyperhomocysteinemia in L-dopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia?
Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurons; Parkinson Disease | 2010 |
Motor complications, levodopa metabolism and progression of Parkinson's disease.
Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission | 2011 |
Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
Topics: Antiparkinson Agents; Databases, Factual; Homocysteine; Humans; Levodopa; Parkinson Disease | 2013 |
[Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
Topics: Catechol O-Methyltransferase Inhibitors; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Vitamin B Complex | 2013 |
Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Cognition Disorders; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Vitamin B 12 | 2017 |
The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms.
Topics: Animals; Diet; Folic Acid; Genetic Predisposition to Disease; Homocysteine; Humans; Levodopa; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Nutritional Status; One-Carbon Group Transferases; Parkinson Disease; Polymorphism, Genetic; Vitamin B Complex | 2019 |
Levodopa, homocysteine and Parkinson's disease: What's the problem?
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamin B Complex | 2023 |
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerations.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine; Homocysteine; Humans; Levodopa; Parkinson Disease; Vitamin B 12; Vitamins | 2023 |
18 trial(s) available for homocysteine and levodopa
Article | Year |
---|---|
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Pyridoxal Phosphate; Risk Factors; Vitamin B 12; Vitamin B Complex | 2003 |
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Catechols; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; Humans; Levodopa; Linear Models; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2005 |
Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12 | 2005 |
The effect of entacapone on homocysteine levels in Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Treatment Outcome | 2005 |
Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Prospective Studies; S-Adenosylhomocysteine; Tolcapone | 2006 |
Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Threonine; Time Factors | 2006 |
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Topics: Aged; Antiparkinson Agents; Canada; Catechols; Double-Blind Method; Drug Combinations; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Placebo Effect; Treatment Outcome; United States; Vitamin B 12; Vitamins | 2006 |
Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Cognition; Enzyme-Linked Immunosorbent Assay; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Statistics, Nonparametric; Vitamin B 12 | 2006 |
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2009 |
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Dementia; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Parkinson Disease | 2009 |
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors; Tyrosine | 2009 |
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Homocysteine; Humans; Levodopa; Memantine; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2010 |
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 2011 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
Serum homocysteine and physical exercise in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Exercise; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Mental Status Schedule; Middle Aged; Parkinson Disease | 2011 |
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2016 |
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Research Design; Vitamin B 12 | 2021 |
Parkinson's disease: Research puts spotlight on thiamine deficiency and cardiovascular health.
Topics: Folic Acid; Homocysteine; Humans; Levodopa; Parkinson Disease; Thiamine Deficiency; Vitamin B 12 | 2021 |
62 other study(ies) available for homocysteine and levodopa
Article | Year |
---|---|
Tropolone antagonism of the L-dopa-induced elevation of S-adenosylhomocysteine: S-adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Epinephrine; Homocysteine; Hypothalamus; Levodopa; Male; Rats; Rats, Inbred Strains; S-Adenosylhomocysteine; S-Adenosylmethionine; Tropolone | 1984 |
Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats.
Topics: Animals; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Cerebellum; Cerebral Cortex; Corpus Striatum; Enzyme Inhibitors; Hippocampus; Homocysteine; Kidney; Levodopa; Liver; Male; Rats; Rats, Sprague-Dawley; S-Adenosylhomocysteine; S-Adenosylmethionine; Spleen | 1997 |
Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carboxy-Lyases; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra; Vascular Diseases | 1999 |
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cysteine; Female; Folic Acid; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Point Mutation | 2000 |
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease | 2001 |
Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.
Topics: Genotype; Homocysteine; Humans; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease | 2001 |
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 2001 |
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Cardiovascular Diseases; Dopa Decarboxylase; Down-Regulation; Drug Interactions; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Up-Regulation | 2001 |
3-OMD and homocysteine plasma levels in parkinsonian patients.
Topics: Dihydroxyphenylalanine; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 2002 |
Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Coronary Artery Disease; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamin B 12 | 2003 |
Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype.
Topics: Aged; Analysis of Variance; Carotid Arteries; Female; Homocysteine; Humans; Hypertrophy; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidoreductases Acting on CH-NH Group Donors; Parkinson Disease; Statistics, Nonparametric; Tunica Intima; Ultrasonography | 2003 |
Levodopa-induced hyperhomocysteinaemia in Parkinson's disease.
Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2003 |
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylation; Parkinson Disease; S-Adenosylmethionine; Vitamin B Complex | 2004 |
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Topics: Antiparkinson Agents; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neopterin; Parkinson Disease; Vitamin B Complex | 2004 |
Levodopa elevates homocysteine: is this a problem?
Topics: Antiparkinson Agents; Brain; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; S-Adenosylmethionine | 2004 |
Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
Topics: Action Potentials; Aged; Antiparkinson Agents; Axons; Chromatography, High Pressure Liquid; Electrophysiology; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neural Conduction; Parkinson Disease; Sural Nerve | 2004 |
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Levodopa; Male; Nitriles; Rats; Rats, Wistar | 2005 |
Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Vitamin B 12 | 2005 |
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2005 |
Endothelial function markers in parkinsonian patients with hyperhomocysteinemia.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Case-Control Studies; E-Selectin; Endothelium, Vascular; Fasting; Female; Homocysteine; Humans; Hyperhomocysteinemia; Intercellular Adhesion Molecule-1; Levodopa; Male; Middle Aged; Nitric Oxide; Parkinson Disease; Superoxide Dismutase | 2005 |
Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Topics: Aged; Case-Control Studies; Cognition Disorders; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2005 |
RETRACTED: Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Cohort Studies; Female; Follow-Up Studies; Fractures, Spontaneous; Hip Fractures; Homocysteine; Humans; Hyperhomocysteinemia; Immobilization; Incidence; Japan; Levodopa; Osteoporosis; Parkinson Disease; Proportional Hazards Models; Risk Factors | 2005 |
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid beta-Peptides; Brain; Causality; Cerebral Amyloid Angiopathy; Cognition Disorders; Creatinine; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Predictive Value of Tests; Vitamin B 12 | 2005 |
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias.
Topics: Cross-Sectional Studies; Dyskinesias; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2006 |
Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Single Nucleotide; Reference Values; Vitamin B 12 | 2006 |
Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.
Topics: Analgesics, Non-Narcotic; Analysis of Variance; Animals; Catechols; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Immunoassay; Levodopa; Male; Nitriles; Nitrous Oxide; Random Allocation; Rats; Rats, Wistar | 2007 |
Neurotoxicity of levodopa: treatment-associated homocysteine increase.
Topics: Animals; Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease | 2007 |
Homocysteine in restless legs syndrome.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Reference Values; Restless Legs Syndrome; Vitamin B 12; Vitamin B 6 | 2008 |
Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Vitamin B 12 | 2007 |
Neuropathy as a potential complication of levodopa use in Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Parkinson Disease; Peripheral Nervous System Diseases; Retrospective Studies; Vitamin B 12 | 2008 |
Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Cognition; Creatinine; Female; Folic Acid; Genotype; Homocysteine; Humans; Inactivation, Metabolic; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Vitamin B Complex | 2009 |
Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
Topics: Analysis of Variance; Case-Control Studies; Female; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Matched-Pair Analysis; Middle Aged; Nerve Degeneration; Parkinson Disease; Reference Values; Statistics, Nonparametric; Vitamin B 12 | 2009 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
Topics: Age Distribution; Aged; Aged, 80 and over; Amino Acid Substitution; Antiparkinson Agents; Base Sequence; Biomarkers; DNA Mutational Analysis; Female; Gene Frequency; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Dehydrogenase (NAD+); Parkinson Disease; Polymorphism, Genetic; Sex Distribution | 2009 |
Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Erythrocytes; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methylation; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; S-Adenosylhomocysteine; S-Adenosylmethionine | 2010 |
Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bone and Bones; Bone Density; Causality; Cohort Studies; Comorbidity; Female; Fractures, Bone; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Up-Regulation | 2010 |
Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients.
Topics: Aged; Cross-Sectional Studies; Dopamine Agents; Female; Genetic Predisposition to Disease; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Secondary Prevention; Treatment Outcome; Vitamin B 12 | 2010 |
L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; Statistics, Nonparametric | 2010 |
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2010 |
Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Duodenum; Female; Home Infusion Therapy; Homocysteine; Humans; Infusions, Parenteral; Levodopa; Male; Methyldopa; Parkinson Disease | 2010 |
Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Area Under Curve; Circadian Rhythm; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Factors; Vitamins | 2010 |
Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Parkinson Disease; Polymorphism, Genetic; Ubiquinone; Vitamin B 12 | 2012 |
Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model.
Topics: Animals; Blotting, Western; Dopamine Agonists; Flow Cytometry; Homocysteine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurogenesis; Parkinson Disease; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Topics: Aged; Catechols; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Nitriles; Parkinson Disease | 2013 |
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
Topics: Aged; Antiparkinson Agents; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk; Vitamin B 12 | 2013 |
Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Electromyography; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Vitamin B 12 | 2014 |
Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Atrophy; Brain; Dilatation; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
Topics: Aged; Antiparkinson Agents; Brachial Artery; Catechols; Dilatation; Endothelium; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Nitriles; Parkinson Disease; Statistics, Nonparametric | 2014 |
L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homocysteine; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2016 |
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides; Dopamine Agents; Electrochemical Techniques; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors; Tyrosine | 2017 |
Serum methylmalonic acid correlates with neuropathic pain in idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylmalonic Acid; Middle Aged; Neural Conduction; Neuralgia; Pain Measurement; Parkinson Disease; Prevalence; Severity of Illness Index; Vitamin B 12 | 2017 |
Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.
Topics: Aged; Catechol O-Methyltransferase; Cognition Disorders; Cross-Sectional Studies; Female; Genotype; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Neuropsychological Tests; Parkinson Disease; Polymorphism, Single Nucleotide; Polyneuropathies; Statistics, Nonparametric; Vitamins | 2017 |
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Polyneuropathies; Statistics, Nonparametric | 2018 |
Clinical utility of SUDOSCAN in predicting autonomic neuropathy in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Electrophysiology; Female; Galvanic Skin Response; Homocysteine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cystatin C; Female; Homocysteine; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Risk Factors; Triglycerides | 2020 |
Peripheral Neuropathy in
Topics: Adult; Aged; Case-Control Studies; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Parkinson Disease; Peripheral Nervous System Diseases; Prevalence; Risk Factors; Uric Acid; Vitamin B 12 | 2020 |
Elevation of Plasma Homocysteine and Minor Hallucinations in Parkinson's Disease: A Cross-Sectional Study.
Topics: Cross-Sectional Studies; Female; Hallucinations; Homocysteine; Humans; Levodopa; Male; Parkinson Disease | 2022 |
Fiber selectivity of peripheral neuropathy in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Homocysteine; Humans; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases | 2022 |
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2022 |
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone | 2022 |
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease | 2023 |